Federated Hermes
ONCT

Federated Hermes’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Federated Hermes’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-65
Closed -$1.3K – 2301
2022
Q4 		$1.3K Sell
65
-7
-10% -$139 ﹤0.01% 2040
2022
Q3 		$1K Buy
72
+39
+118% +$836 ﹤0.01% 2107
2022
Q2 		$1K Buy
33
+10
+43% +$223 ﹤0.01% 2111
2022
Q1 		$1K Buy
+23
New +$837 ﹤0.01% 2141
2018
Q3 		– Sell
-1,054
Closed -$2.26M – 2349
2018
Q2 		$2.26M Buy
1,054
+427
+68% +$1.08M 0.01% 959
2018
Q1 		$1.56M Buy
+627
New +$1.4M ﹤0.01% 1062

Other funds holding ONCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
BIT Capital Berlin, Germany $2.07B AUM 157.17% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
QPW
Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Federated Hermes's ONCT Position: Q1 2023 in Review

Federated Hermes sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q1 2023, closing a stake of 65 shares — an estimated $1.3K sold.

Federated Hermes first reported a position in ONCT in Q1 2018 and held it in 6 quarters. The position peaked at $2.26M in Q2 2018. 54 funds tracked by Wall St. Rank hold ONCT as of Q1 2023.

  • Federated Hermes reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Federated Hermes sold 65 Oncternal Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $1.3K.
  • Federated Hermes first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q1 2018 and held it in 6 quarters.
  • Federated Hermes's Oncternal Therapeutics, Inc. Common Stock position peaked at $2.26M in Q2 2018.
  • 54 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Federated Hermes's 13F filing for Q1 2023, filed 8 May 2023.